MX2010004298A - Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. - Google Patents
Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.Info
- Publication number
- MX2010004298A MX2010004298A MX2010004298A MX2010004298A MX2010004298A MX 2010004298 A MX2010004298 A MX 2010004298A MX 2010004298 A MX2010004298 A MX 2010004298A MX 2010004298 A MX2010004298 A MX 2010004298A MX 2010004298 A MX2010004298 A MX 2010004298A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- agonist activity
- glucagon antagonist
- glucagon
- compounds exhibiting
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 6
- 102000051325 Glucagon Human genes 0.000 title abstract 5
- 108060003199 Glucagon Proteins 0.000 title abstract 5
- 229960004666 glucagon Drugs 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title abstract 3
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 title 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98376607P | 2007-10-30 | 2007-10-30 | |
| US9044108P | 2008-08-20 | 2008-08-20 | |
| PCT/US2008/081333 WO2009058734A1 (en) | 2007-10-30 | 2008-10-27 | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010004298A true MX2010004298A (es) | 2010-05-03 |
Family
ID=40591418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010004298A MX2010004298A (es) | 2007-10-30 | 2008-10-27 | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8980830B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2214691B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5771005B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR069136A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008318876B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2702289A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2008003243A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2558155T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010004298A (cg-RX-API-DMAC7.html) |
| PA (1) | PA8802301A1 (cg-RX-API-DMAC7.html) |
| PE (1) | PE20090932A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200920395A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009058734A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2572952T3 (es) | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
| RU2477286C2 (ru) * | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
| US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| CA2713348C (en) * | 2008-01-30 | 2018-10-09 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| AR072160A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| WO2009155257A1 (en) * | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| WO2010011439A2 (en) | 2008-06-17 | 2010-01-28 | Indiana University Research And Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| AU2009327418A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| US9150632B2 (en) * | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| GB0917072D0 (en) * | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| EP2501685A1 (en) | 2009-11-16 | 2012-09-26 | Mellitech | [1,5]-diazocin derivatives |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| US8551946B2 (en) * | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US9145451B2 (en) * | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
| JP6121323B2 (ja) | 2010-05-13 | 2017-05-10 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| EP2635296B1 (en) | 2010-11-03 | 2014-12-24 | Arecor Limited | Novel composition comprising glucagon |
| PE20140186A1 (es) | 2010-12-22 | 2014-02-13 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
| US9790262B2 (en) | 2011-04-05 | 2017-10-17 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
| SI2718318T1 (sl) | 2011-06-10 | 2018-11-30 | Hanmi Science Co., Ltd. | Novi derivati oksintomodulina in le-te obsegajoča farmacevtska sestava za zdravljenje debelosti |
| ES2710356T3 (es) | 2011-06-17 | 2019-04-24 | Hanmi Science Co Ltd | Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo |
| JP6179864B2 (ja) | 2011-06-22 | 2017-08-16 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト |
| CN103748109A (zh) | 2011-06-22 | 2014-04-23 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共同激动剂 |
| US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2780031B1 (en) | 2011-11-17 | 2018-03-07 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| US9452225B2 (en) | 2012-03-01 | 2016-09-27 | Novo Nordisk A/S | GLP-1 prodrugs |
| CN112142855A (zh) | 2012-05-18 | 2020-12-29 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| TWI652071B (zh) | 2012-11-06 | 2019-03-01 | 韓美藥品股份有限公司 | 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑 |
| TWI617574B (zh) * | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| CA2895875A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 derivatives |
| WO2014158900A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| AU2014359894B2 (en) | 2013-12-06 | 2020-09-17 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| EP3206710B1 (en) | 2014-09-24 | 2020-05-06 | Indiana University Research & Technology Corporation | Incretin-insulin conjugates |
| MA55068A (fr) | 2014-10-24 | 2022-01-05 | Merck Sharp & Dohme | Co-agonistes des récepteurs du glucagon et du glp-1 |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| CN110204617B (zh) * | 2014-12-31 | 2023-06-16 | 天境生物科技(上海)有限公司 | 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途 |
| EP3273981B1 (en) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
| WO2017062271A2 (en) | 2015-10-06 | 2017-04-13 | Merck Sharp & Dohme Corp. | Antibody drug conjugate for anti-inflammatory applications |
| EP3407916B1 (en) | 2016-01-29 | 2023-12-20 | Merck Sharp & Dohme LLC | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| WO2017210100A1 (en) * | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Glucagon-like peptide-1-t3 conjugates |
| WO2017210168A1 (en) * | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Aqueously soluble and chemically stable depsi glucagon agonists |
| GB201611077D0 (en) | 2016-06-24 | 2016-08-10 | Arecor Ltd | Novel composition |
| CN110799521A (zh) * | 2017-02-15 | 2020-02-14 | 拜奥普罗塞亚科技有限责任公司 | 具有温和洗脱pH的亲和色谱配体 |
| EP3624828B1 (en) | 2017-05-18 | 2024-08-07 | Merck Sharp & Dohme LLC | Pharmaceutical formulation comprising incretin-insulin conjugates |
| CN116143939A (zh) * | 2017-11-24 | 2023-05-23 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多重活性蛋白 |
| IL311775A (en) | 2018-01-03 | 2024-05-01 | Mederis Diabetes Llc | Improved peptide drugs for the treatment of NASH and other disorders |
| MY202560A (en) | 2018-04-05 | 2024-05-08 | Sun Pharmaceutical Ind Ltd | Novel glp-1 analogues |
| CN111269321B (zh) * | 2018-12-04 | 2023-05-12 | 鲁南制药集团股份有限公司 | 一种glp-1类似物融合蛋白质 |
| CA3195925A1 (en) * | 2020-10-30 | 2022-05-05 | Robin Elaine DUNCAN | Modulation of glucagon-like peptide 1 and uses thereof |
| CN117202924A (zh) | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275152A (en) * | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5539084A (en) * | 1989-02-17 | 1996-07-23 | Coselco Mimotopes Pty. Ltd. | Method for the use and synthesis of peptides |
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
| CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| US5510459A (en) * | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
| WO1997013500A2 (en) | 1995-10-12 | 1997-04-17 | Supergen, Inc. | LIPOSOME FORMULATIONS OF 5β STEROIDS |
| WO1997029180A1 (en) | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
| CN1183158C (zh) | 1996-06-05 | 2005-01-05 | 罗赫诊断器材股份有限公司 | Exendin类似物,其制备方法及含有它们的药物制剂 |
| WO1998011126A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| WO1998024464A1 (en) | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| DE19828113A1 (de) * | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| US20030236190A1 (en) * | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| EP1119625B1 (en) | 1998-10-07 | 2005-06-29 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| PL202367B1 (pl) | 1998-12-07 | 2009-06-30 | Sod Conseils Rech Applic | Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| AU2001257278A1 (en) | 2000-04-27 | 2001-11-07 | Bionebraska, Inc. | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
| US6677136B2 (en) * | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| CA2410604A1 (en) * | 2000-06-14 | 2001-12-20 | Cytovax Biotechnologies, Inc. | Use of coiled-coil structural scaffold to generate structure-specific peptides |
| KR100847615B1 (ko) | 2000-06-16 | 2008-07-21 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드-1 유사체 |
| US20030204063A1 (en) * | 2000-08-02 | 2003-10-30 | Denis Gravel | Modified biological peptides with increased potency |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| ATE516820T1 (de) * | 2000-09-29 | 2011-08-15 | Schering Corp | Pegyliertes interleukin 10 |
| AU2002228608A1 (en) | 2000-12-13 | 2002-06-24 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
| AU2002327430A1 (en) * | 2001-08-08 | 2003-02-24 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
| WO2003020201A2 (en) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7041646B2 (en) * | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| AR036711A1 (es) * | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US7238670B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| MXPA04003569A (es) | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
| AU2002351752A1 (en) * | 2001-12-29 | 2003-07-30 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| MXPA04006679A (es) | 2002-01-08 | 2004-11-10 | Lilly Co Eli | Analogos extendidos de peptido-1 de tipo glucagon. |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| US20060252916A1 (en) * | 2002-06-04 | 2006-11-09 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
| WO2003103697A2 (en) | 2002-06-11 | 2003-12-18 | Cell Therapeutics Scandinavia Ab | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
| CA2489323A1 (en) | 2002-06-15 | 2003-12-24 | Enteromed, Inc. | Treatment of non-alcoholic fatty liver disease |
| EP1539210A4 (en) | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE |
| US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| EP1626981A4 (en) | 2003-03-04 | 2006-11-22 | Biorexis Pharmaceutical Corp | PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE |
| JP2006520818A (ja) * | 2003-03-19 | 2006-09-14 | イーライ リリー アンド カンパニー | ポリエチレングリコール結合ｇｌｐ−１化合物 |
| CA2521784C (en) * | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2004103390A2 (en) | 2003-05-15 | 2004-12-02 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| JP2007524592A (ja) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー／エス | 安定化された薬学的ペプチド組成物 |
| EP1633390B1 (en) | 2003-06-03 | 2012-01-18 | Novo Nordisk A/S | Stabilized pharmaceutical glp-1 peptide compositions |
| UA87458C2 (ru) * | 2003-06-12 | 2009-07-27 | Елі Ліллі Енд Компані | Гибридные белки-аналоги glp-1 |
| US20050124550A1 (en) * | 2003-06-18 | 2005-06-09 | Peri Krishna G. | Compounds that modulate the glucagon response and uses thereof |
| AU2004273573B2 (en) * | 2003-09-19 | 2010-04-22 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| US7364875B2 (en) * | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
| WO2005058954A1 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 compounds |
| US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| BRPI0606992A2 (pt) * | 2005-02-11 | 2009-07-28 | Amylin Pharmaceuticals Inc | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis |
| US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| EP1863537A2 (en) * | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| ATE482724T1 (de) | 2005-05-13 | 2010-10-15 | Lilly Co Eli | Pegylierte glp-1-verbindungen |
| EP1891105B1 (en) | 2005-06-13 | 2012-04-11 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| WO2007028633A2 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Treatment of diabetes related obesity |
| US20090286722A1 (en) | 2005-09-08 | 2009-11-19 | Utech Limited | Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function |
| ES2572952T3 (es) * | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
| AU2007221366B2 (en) | 2006-02-22 | 2012-08-23 | Msd Italia S.R.L. | Oxyntomodulin derivatives |
| CN101389647A (zh) * | 2006-02-28 | 2009-03-18 | 伊莱利利公司 | 选择性vpac2受体肽激动剂 |
| EP1996224B1 (en) * | 2006-03-15 | 2012-11-07 | Novo Nordisk A/S | Mixtures of amylin and insulin |
| JP5412273B2 (ja) | 2006-03-21 | 2014-02-12 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | ペプチド−ぺプチダーゼ阻害剤及びその使用 |
| EP2573111A1 (en) | 2006-04-20 | 2013-03-27 | Amgen Inc. | GLP-1 compounds |
| WO2008022015A2 (en) | 2006-08-11 | 2008-02-21 | Trustees Of Tufts College | Retro-inverso incretin analogues, and methods of use thereof |
| AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| CN104193815A (zh) * | 2006-09-08 | 2014-12-10 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| RU2477286C2 (ru) * | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| MX2009008241A (es) * | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| DK2158214T3 (da) * | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
| US7859468B2 (en) * | 2007-08-30 | 2010-12-28 | Research In Motion Limited | Mobile wireless communications device including a folded monopole multi-band antenna and related methods |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| EP2650006A1 (en) | 2007-09-07 | 2013-10-16 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
| WO2009034117A1 (en) | 2007-09-11 | 2009-03-19 | Novo Nordisk A/S | Mixture comprising an amylin peptide and a protracted insulin |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
| US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| CN101918027A (zh) | 2007-11-02 | 2010-12-15 | 森托科尔奥索生物科技公司 | 半合成GLP-1肽-Fc融合构造、方法及其用途 |
| CA2713348C (en) | 2008-01-30 | 2018-10-09 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| HUE044174T2 (hu) | 2008-02-01 | 2019-10-28 | Ascendis Pharma As | Önhasítható linkert tartalmazó elõvegyület |
| WO2010011439A2 (en) | 2008-06-17 | 2010-01-28 | Indiana University Research And Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| AR072160A1 (es) * | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| KR20110114568A (ko) | 2008-12-19 | 2011-10-19 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 디펩티드 링크된 약효 물질 |
| AU2009327418A1 (en) * | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| JP6121323B2 (ja) | 2010-05-13 | 2017-05-10 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
-
2008
- 2008-10-27 US US12/740,206 patent/US8980830B2/en not_active Expired - Fee Related
- 2008-10-27 MX MX2010004298A patent/MX2010004298A/es active IP Right Grant
- 2008-10-27 WO PCT/US2008/081333 patent/WO2009058734A1/en not_active Ceased
- 2008-10-27 ES ES08845541.5T patent/ES2558155T3/es active Active
- 2008-10-27 JP JP2010532174A patent/JP5771005B2/ja not_active Expired - Fee Related
- 2008-10-27 EP EP08845541.5A patent/EP2214691B1/en not_active Not-in-force
- 2008-10-27 CA CA2702289A patent/CA2702289A1/en not_active Abandoned
- 2008-10-27 AU AU2008318876A patent/AU2008318876B2/en not_active Ceased
- 2008-10-30 CL CL2008003243A patent/CL2008003243A1/es unknown
- 2008-10-30 PA PA20088802301A patent/PA8802301A1/es unknown
- 2008-10-30 AR ARP080104771A patent/AR069136A1/es unknown
- 2008-10-30 PE PE2008001855A patent/PE20090932A1/es not_active Application Discontinuation
- 2008-10-30 TW TW097141893A patent/TW200920395A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009058734A1 (en) | 2009-05-07 |
| JP2011502159A (ja) | 2011-01-20 |
| EP2214691A4 (en) | 2011-01-05 |
| EP2214691B1 (en) | 2015-09-30 |
| PE20090932A1 (es) | 2009-07-15 |
| WO2009058734A4 (en) | 2009-07-23 |
| ES2558155T3 (es) | 2016-02-02 |
| CL2008003243A1 (es) | 2009-02-27 |
| EP2214691A1 (en) | 2010-08-11 |
| AR069136A1 (es) | 2009-12-30 |
| AU2008318876B2 (en) | 2014-05-15 |
| JP5771005B2 (ja) | 2015-08-26 |
| TW200920395A (en) | 2009-05-16 |
| PA8802301A1 (es) | 2009-06-23 |
| US20110098217A1 (en) | 2011-04-28 |
| AU2008318876A1 (en) | 2009-05-07 |
| US8980830B2 (en) | 2015-03-17 |
| CA2702289A1 (en) | 2009-05-07 |
| HK1141984A1 (en) | 2010-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010004298A (es) | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. | |
| NZ589847A (en) | Glucagon/glp-1 receptor co-agonists | |
| MY167814A (en) | Long-acting oxyntomodulin variants and methods of producing same | |
| MX2010004297A (es) | Antagonistas de glucagon. | |
| ES2529612T3 (es) | Composición farmacéutica para tratar un síndrome metabólico | |
| WO2011075393A3 (en) | Glucagon/glp-1 receptor co-agonists | |
| CY1116917T1 (el) | Αναλογα οξυντομοντουλινης | |
| NZ740644A (en) | Glucagon receptor agonists | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| GEP20176629B (en) | Glucagon/glp-1 receptor co-agonists | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| IN2012DN00377A (cg-RX-API-DMAC7.html) | ||
| MX346957B (es) | Agonistas de receptor de glp-1/glucagón de acción prolongada. | |
| AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
| MX2010012695A (es) | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. | |
| PE20170954A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| PH12014500922A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| MY156188A (en) | Long - acting formulations of insulins | |
| BR112012027893A2 (pt) | peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada. | |
| BR112012027545A8 (pt) | Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto | |
| EP2344519A4 (en) | C-TERMINAL FRUCTIONS OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) | |
| CL2012001657A1 (es) | Polipeptidos de somatotropina porcina porque comprende un aminoacido no codificado de manera natural; uso de dicho polipeptido porque sirve para prevenir infeccion en animal. | |
| NZ596501A (en) | Casb7439 constructs | |
| PH12018501319A1 (en) | Insulinotropic peptide derivative with modified n-terminal charge | |
| NZ601616A (en) | Method for producing interferon alpha 5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |